Pharma Focus Asia

PharmaBlock Plans to Expand New R&D Facility Operations in Pennsylvania, USA

Introduction:

PharmaBlock plans to expand its R&D operations to deliver GMP projects with the opening of new facility.

Features:

This expanded footprint will enable to more efficiently process R&D services for the rapid delivery of clinical-phase GMP projects to global partners.

The state-of-the-art facility will provide clients with the highest quality research and development solutions. It joins the existing facility and enhance the delivery of clinical-stage API projects.

The new site cosnisting of 30,000 ft2 of laboratory space also includes process research and development laboratories, GMP suites, clean rooms and GMP analytical laboratories. Moreover, the facility allows for flow chemistry, micro-packed bed hydrogenation, and solid-state chemistry capabilities.

In addition, a GMP production facility for intermediates and APIs with 500-2,000 litre reactors are planned for the West Chester plant, which is expected to be operational in 2024.

Specifications:

Name    PharmaBlock
Type      New Construction

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products ConferenceĀ 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024